AWA
EPIX

Alta Wealth Advisors’s ESSA Pharma EPIX Stock Holding History

Alta Wealth Advisors’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,285
Closed -$21K – 145
2022
Q3 		$21K Hold
11,285
– – 0.02% 136
2022
Q2 		$36K Hold
11,285
– – 0.02% 137
2022
Q1 		$70K Buy
+11,285
New +$99.2K 0.04% 144

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Alta Wealth Advisors's EPIX Position: Q4 2022 in Review

Alta Wealth Advisors sold out of ESSA Pharma (EPIX) in Q4 2022, closing a stake of 11,285 shares — an estimated $21K sold.

Alta Wealth Advisors first reported a position in EPIX in Q1 2022 and held it in 3 quarters. The position peaked at $70K in Q1 2022. 45 funds tracked by Wall St. Rank hold EPIX as of Q4 2022.

  • Alta Wealth Advisors reported no remaining ESSA Pharma position as of Q4 2022 after selling out during the quarter.
  • Alta Wealth Advisors sold 11,285 ESSA Pharma shares in Q4 2022, an estimated $21K.
  • Alta Wealth Advisors first reported a position in ESSA Pharma in Q1 2022 and held it in 3 quarters.
  • Alta Wealth Advisors's ESSA Pharma position peaked at $70K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2022.

Based on Alta Wealth Advisors's 13F filing for Q4 2022, filed 20 Jan 2023.